Please login to the form below

Not currently logged in
Email:
Password:

UCB reports H1 profit rise

UCB's profit has been boosted by increased sales of core drugs

UCB, the Belgian pharmaceutical company, has posted an 11 per cent increase in pre-tax profit to €443m for the first six months of 2011, reflecting a strong increase in sales.

The company's total revenue for the period increased by 2 per cent to €1.68bn. It reported significant sales growth of new medicines Cimzia (certolizumab pegol - 72 per cent), Vimpat (lacosamide - 76 per cent) and Neupro (rotigotine - 17 per cent). UCB also noted a strong performance of its anti-epileptic drug Keppra (levetiracetam) in Europe and Japan.

Roch Doliveux, CEO, said: "We are excited about the momentum of Cimzia, Vimpat and Neupro, about the potential UCB new medicines from our promising pipeline and about the fact that from 2012 onward, we will have a decade without impacts from major patent expiries."

The company's pipeline has been strengthened with positive phase III results for Cimzia in rheumatoid arthritis and Neupro for advanced Parkinson's disease.

29th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics